• GLP-1 (9-36) amide: Selective GLP-1 Receptor Antagonist for

  2026-07-31

  GLP-1 (9-36) amide is a rigorously validated glucagon-like peptide-1 receptor antagonist used in metabolic and GPCR signaling research. Its defined specificity and stability support reproducible assays in type 2 diabetes and endocrine studies.

• Salvianolic acid B: Advanced Protocols for Pulmonary Fibrosi

  2026-07-30

  Salvianolic acid B (Dan Shen Suan B) is redefining pulmonary fibrosis research by precisely targeting LH2-mediated collagen cross-linking. This guide decodes state-of-the-art workflows, protocol parameters, and troubleshooting tactics for maximizing its antifibrotic impact in extracellular matrix remodeling studies.

• Diphenyleneiodonium Chloride: Precision Tool for Redox Biolo

  2026-07-30

  Diphenyleneiodonium chloride (DPI) uniquely bridges redox enzyme inhibition and cAMP signaling modulation, empowering advanced oxidative stress and GPCR research. This guide delivers actionable workflows, troubleshooting insights, and domain-spanning innovations for robust experimental outcomes.

• PX-478 2HCl Mitigates ASD Progression in Prenatal Hypoxia Ra

  2026-07-29

  This study demonstrates that PX-478 2HCl, a HIF-1α inhibitor, alleviates autism-like behaviors in rat offspring subjected to prenatal hypoxia. The findings reveal mechanistic insights into hypoxia-induced neurodevelopmental disruption and highlight the therapeutic research potential of hypoxia pathway modulation in ASD models.

• Hexose Diphosphate: Precision Workflows in Energy & Inflamma

  2026-07-29

  Hexose diphosphate, a pivotal glycolytic intermediate, empowers high-resolution dissection of metabolic flux and inflammatory signaling in cardiovascular and aging research. This article delivers actionable protocols, troubleshooting strategies, and advanced use-cases, translating novel bench findings into robust experimental success.

• Tunicamycin as a Precision Tool for Modeling ER Stress Pathw

  2026-07-28

  Explore Tunicamycin’s unique role as a N-glycosylation inhibitor in dissecting endoplasmic reticulum stress and inflammation mechanisms. This article offers advanced, evidence-based insight for researchers seeking to model ER stress with scientific rigor.

• KN-62: Precision CaMKII Inhibition for Translational Discove

  2026-07-28

  This thought-leadership article explores how KN-62, a highly selective CaMKII inhibitor, enables translational researchers to dissect calcium signaling and cell cycle dynamics with unprecedented precision. Integrating mechanistic insights with actionable protocol guidance, the piece bridges fundamental neuroscience—highlighting recent advances in social memory maintenance—with strategic experimental design for metabolic and cellular research. The article positions APExBIO's KN-62 as a catalyst for innovation, emphasizing evidence-backed approaches and competitive differentiation for next-generation translational workflows.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-07-27

  Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine enables precision immune modulation in α2-adrenergic receptor signaling research, with a focus on post-surgery osteosarcoma recurrence. This in-depth analysis reveals practical assay implications and novel mechanistic insights not covered in existing literature.

• Stable Isotope-Diluted UHPLC–MS/MS for Methylated Purine Nuc

  2026-07-27

  This study introduces a highly sensitive and precise UHPLC–MS/MS method utilizing stable isotope dilution to quantify ten methylated purine nucleosides, including 1-methyl Adenosine, in cellular contexts. The approach overcomes longstanding analytical challenges, supporting biomarker discovery and advancing RNA modification research in cancer and disease models.

• Phytol: Mechanistic Leverage and Strategic Edge in Translati

  2026-07-26

  Explore how Phytol, a natural diterpene alcohol, drives innovation in retinoid X receptor signaling and GABAergic modulation, offering translational researchers unique mechanistic leverage and a strategic edge. This article synthesizes current mechanistic insights, protocol parameters, and real-world workflow guidance, positioning Phytol as an indispensable tool—backed by both literature and product intelligence from APExBIO—for the next generation of nuclear hormone receptor and neuropharmacology studies.

• Nuclear cGAS-TRIM41 Axis Suppresses L1 Retrotransposition vi

  2026-07-25

  The referenced study uncovers that nuclear cGAS, upon phosphorylation by Chk2, promotes TRIM41-mediated ubiquitination and degradation of L1 ORF2p, thereby suppressing LINE-1 retrotransposition and maintaining genome stability. This posttranslational regulatory mechanism expands our understanding of cGAS function in DNA damage response and has implications for aging and cancer biology.

• TMEM16F in Kupffer Cells Regulates Liver Inflammation in Lis

  2026-07-24

  This study elucidates the essential role of TMEM16F in liver Kupffer cells for protecting against Listeria monocytogenes infection, highlighting its function in plasma membrane repair and the regulation of inflammation and liver metabolism. The findings clarify cell-specific mechanisms in host defense, offering new directions for dissecting inflammatory liver injury.

• Azilsartan (TAK-536): Mechanistic Insights for RAS–SIRT3 Res

  2026-07-24

  Azilsartan (TAK-536) is a potent AT1 receptor inverse agonist widely used to dissect the renin-angiotensin system and SIRT3 axis in cardiovascular and neuroinflammation research. By selectively inhibiting AT1, Azilsartan enables precise modulation of astrocyte–microglia signaling, as demonstrated in recent mechanistic studies. Its high specificity and solubility profile make it a benchmark tool for modeling RAS-dependent pathways.

• Lovastatin as an HMG-CoA Reductase Inhibitor: Applied Workfl

  2026-07-23

  Lovastatin's nanomolar inhibition of HMG-CoA reductase positions it as a cornerstone for studying cholesterol metabolism, apoptosis, and cell proliferation. This article delivers actionable protocols, troubleshooting, and cross-domain insights for maximizing experimental impact with APExBIO’s Lovastatin.

• COX Inhibitors in Canine Mammary Tumor Cells: Cytotoxic Syne

  2026-07-23

  This study investigates the antiproliferative and pro-apoptotic effects of piroxicam and deracoxib, both individually and in combination, on the canine mammary carcinoma cell line CMT-U27. The findings reveal a synergistic cytotoxic effect at lower concentrations when both drugs are combined, providing new insights into chemopreventive approaches for canine mammary carcinoma.

459 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page